Oxford Nanopore reversed an earlier deprecation plan and will extend hardware and software support for its PromethIon 2 Solo (P2 Solo) sequencer through 2030 after customer backlash. The company will stop sales this summer but pledged compatibility, support and updates until the extended date to allow labs time to transition workflows and purchasing plans. Separately Devyser announced an instrument distribution model to sell certain Illumina sequencing instruments bundled with reagent commitments rather than traditional capital purchase, signaling vendor flexibility on site infrastructure and reagent economics. Together the moves reflect vendor sensitivity to lab procurement cycles and the importance of platform continuity for genomics workflows; customers flagged affordability, throughput needs and long‑term assay compatibility in pushing vendors to modify exit plans or commercial terms.